These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11574430)

  • 1. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes.
    Moran A; Phillips J; Milla C
    Diabetes Care; 2001 Oct; 24(10):1706-10. PubMed ID: 11574430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug treatments for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD004730. PubMed ID: 33075159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin and oral agents for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2016 Apr; 4():CD004730. PubMed ID: 27087121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus.
    Ballmann M; Hubert D; Assael BM; Kronfeld K; Honer M; Holl RW;
    BMC Pediatr; 2014 Mar; 14():70. PubMed ID: 24620855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.
    Malone JK; Woodworth JR; Arora V; Yang H; Campaigne BN; Hallé JP; Yale JF; Grossman LD
    Clin Ther; 2000 Feb; 22(2):222-30. PubMed ID: 10743981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.
    Rassam AG; Zeise TM; Burge MR; Schade DS
    Diabetes Care; 1999 Jan; 22(1):133-6. PubMed ID: 10333914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin and oral agents for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2013 Jul; (7):CD004730. PubMed ID: 23893261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.
    Moran A; Pekow P; Grover P; Zorn M; Slovis B; Pilewski J; Tullis E; Liou TG; Allen H;
    Diabetes Care; 2009 Oct; 32(10):1783-8. PubMed ID: 19592632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
    Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
    Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro).
    Rabasa-Lhoret R; Bourque J; Ducros F; Chiasson JL
    Diabetes Care; 2001 Apr; 24(4):625-30. PubMed ID: 11315820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
    Van Gaal LF; Van Acker KL; De Leeuw IH
    Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
    Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
    Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM.
    Burge MR; Castillo KR; Schade DS
    Diabetes Care; 1997 Feb; 20(2):152-5. PubMed ID: 9118763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.